A new study identified several metabolites and metabolic indicators as potential biomarkers for recurrence risk in non–muscle-invasive bladder cancer.
A large genomic analysis identified more than 60 new prostate cancer susceptibility loci, including one locus significantly associated with early onset.
An antigen-specific immunotherapeutic known as MAGE-A3 was no better than placebo for the adjuvant treatment of stage IIIB or IIIC melanoma.
In women with ovarian cancer, those with early life adversity and anxiety had more dysregulation of cortisol, suggesting they may be at risk for more negative outcomes.
A phase II study found that the FGFR inhibitor erdafitinib yields a good response rate and was well tolerated in patients with urothelial carcinoma and FGFR alterations.
Treatment with the second-generation EGFR TKI dacomitinib resulted in improved overall survival over gefitinib in patients with NSCLC and activating EGFR mutations.
The trastuzumab biosimilar ABP 980 showed noninferiority to trastuzumab in a large trial of patients with early HER2-positive breast cancer.
The combination of the PARP inhibitor olaparib and abiraterone offered improved efficacy in patients with metastatic castration-resistant prostate cancer, but at what cost?
Nab-paclitaxel/carboplatin should be considered a first-line option in the setting of triple-negative breast cancer.
The HER2 TKI tucatinib plus capecitabine or trastuzumab were reasonably well tolerated and showed antitumor activity in a phase I trial of HER2+ breast cancer.